Zacks Investment Research lowered shares of vTv Therapeutics Inc. (NASDAQ:VTVT) from a buy rating to a sell rating in a research report sent to investors on Wednesday.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
Other equities research analysts have also issued reports about the company. HC Wainwright restated a buy rating and set a $13.00 price target on shares of vTv Therapeutics in a research report on Thursday, March 30th. Piper Jaffray Companies restated an overweight rating and set a $24.00 price target on shares of vTv Therapeutics in a research report on Thursday, March 30th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $14.30.
Shares of vTv Therapeutics (NASDAQ:VTVT) opened at 5.10 on Wednesday. vTv Therapeutics has a 52 week low of $4.56 and a 52 week high of $7.50. The firm’s 50-day moving average price is $4.91 and its 200 day moving average price is $5.43. The company’s market cap is $49.43 million.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.44) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.44). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.20 million. On average, equities analysts predict that vTv Therapeutics will post ($1.16) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “vTv Therapeutics Inc. (VTVT) Downgraded by Zacks Investment Research” was posted by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.wkrb13.com/markets/2284671/vtv-therapeutics-inc-vtvt-downgraded-by-zacks-investment-research.html.
Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares during the period. Essex Investment Management Co. LLC acquired a new stake in vTv Therapeutics during the first quarter worth approximately $261,000. Renaissance Technologies LLC raised its stake in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock worth $294,000 after buying an additional 11,901 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in vTv Therapeutics during the first quarter valued at about $917,000. Finally, Sphera Funds Management LTD. increased its position in vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock valued at $1,965,000 after buying an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 11.12% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284671/vtv-therapeutics-inc-vtvt-downgraded-by-zacks-investment-research.html
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.